Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 16/20 | 0.73 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.65 |
| ▸ | HTR2A | P28223 | 1/20 | 0.65 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636661 | 0.95 | MPO (0.72) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7845587 | 0.89 | MPO (0.71) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL8806598 | 0.88 | HTR2A (0.65) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL3705476 | 0.84 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7846163 | 0.84 | MPO (0.77) | MPOSLC6A4HTR2ATRPM8 | |
| SCHEMBL5203031 | 0.84 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL5584045 | 0.84 | MPO (0.73) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL7819881 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL2403830 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A | |
| SCHEMBL6972588 | 0.83 | MPO (1.00) | MPOSLC6A4HTR2ATRPM8HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1464641-B1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | LUNDBECK & CO AS H (DK) | 2008-05-14 | — | — | EP | disclosed |
| US-7223765-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| CN-1803784-A | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | LUNDBECK CO AS H (DK) | 2006-07-19 | — | — | CN | disclosed |
| US-7074796-B2 | 4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-11 | — | — | US | disclosed |
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2006-07-06 | — | — | US | disclosed |
| CN-1244577-C | 4-phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridinyl derivatives | LUNDBECK & CO AS H (DK) | 2006-03-08 | — | — | CN | disclosed |
| EP-1464641-A1 | 4-Phenyl-piperazinyl, -piperidinyl and tetrahydropyridyl derivatives as dopamine D4 antagonists | H. Lundbeck A/S (DK) | 2004-10-06 | — | — | EP | disclosed |
| EP-1246815-B1 | PHENYLPIPERAZINYL DERIVATIVES | LUNDBECK & CO AS H (DK) | 2004-03-17 | — | — | EP | disclosed |
| CN-1437596-A | Phenylpiperazinyl derivatives | LUNDBECK & CO AS H (DK) | 2003-08-20 | — | — | CN | disclosed |
| CN-1434819-A | 4-phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridinyl derivatives | LUNDBECK & CO AS H (DK) | 2003-08-06 | — | — | CN | disclosed |
| US-20030083336-A1 | Phenylpiperazinyl derivatives | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | H. LUNDBECK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| EP-1246817-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049679-A1 | 4-PHENYL-1-PIPERAZINYL, -PIPERIDINYL AND -TETRAHYDROPYRIDYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
| CN-1047385-C | 3-indolylpiperidine | MERCK PATENT GMBH (DE) | 1999-12-15 | — | — | CN | disclosed |
| EP-0683166-B1 | 3-Indolylpiperidines | MERCK PATENT GMBH (DE) | 1998-10-28 | — | — | EP | disclosed |
| US-5693655-A | 3-indolylpiperidines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-12-02 | — | — | US | disclosed |
| CN-1114651-A | 3-indolylpiperidine | MERCK PATENT GMBH (DE) | 1996-01-10 | — | — | CN | disclosed |
| EP-0683166-A1 | 3-Indolylpiperidines | MERCK PATENT GmbH (DE) | 1995-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148815-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and-tetrahydropyridyl derivatives | OPRD1, VDR, GPR4 | MPO 3687/4885SLC6A4 208/4885HTR2A 646/4885 |
| US-20030083336-A1 | Phenylpiperazinyl derivatives | DRD4, DRD2, DRD3 | MPO 2835/4885SLC6A4 39/4885HTR2A 58/4885 |
| US-20030027832-A1 | 4-Phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives | OPRD1, DRD3, DRD2 | MPO 4559/4885SLC6A4 679/4885HTR2A 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.